Zentalis Pharmaceuticals, Inc.

Stage 4 · Declining · week 2

As of Oct 22, 2026, Zentalis Pharmaceuticals is in Stage 4, the downtrend phase, now in week 2 (since Oct 14, 2026). It closed at $2.41, 63.5% below its 52-week high and below its 200-day average, which is rising.

$2.41

+2.12% today

$236M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is ZNTL early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 15w

S4 26w

S4 34w

S2 35w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 3w → S3 6w → S4 15w → S1 7w → S4 3w → S1 4w → S4 26w → S1 4w → S4 34w → S1 12w → S2 1w → S4 9w → S2 35w → S3 4w → S4 1w current

Total tracked: 165 weeks across 15 stage runs.

ZNTL among Biotechnology98th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…98	ZNTLZentalis Pharmaceuticals, Inc.	Stage 4 · wk 2	85	−16.0%

vs 52W High

-63.5%

$1.28 lo$6.61 hi

63.5% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 2

1w13w26w

Week 2, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-30.9%

200 DMA: $3.49 · rising

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.60x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-16.0%

-44.3%

-38.0%

YTD

+75.9%

+47.0%

Scan Membership

Breakout Watch

Latest: 2023-06-02

4 appearances in last 60 days. First seen: 2021-01-19.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 2 · Vol 0.60x

2026-10-21S4

Wk 2 · Vol 0.91x

2026-10-20S4

Wk 1 · Vol 1.28x

2026-10-19S4

Wk 1 · Vol 2.29x

2026-10-16S4

Wk 1 · Vol 0.93x

2026-10-15S4

Wk 1 · Vol 1.76x

2026-10-14S43→4

Wk 1 · Vol 0.75x

2026-10-13S3

Wk 5 · Vol 0.49x

2026-10-12S3

Wk 5 · Vol 0.47x

2026-10-09S3

Wk 4 · Vol 0.52x

2026-10-08S3

Wk 4 · Vol 1.09x

2026-10-07S3

Wk 4 · Vol 0.70x

Moving averages & range

50 DMA

$3.16

200 DMA

$3.49

52W High

$6.61

52W Low

$1.28

5D Low

$2.13

Resistance levels (recent highs)

20d High

$2.78

60d High

$5.00

120d High

$5.11

250d High

$6.61

Next resistance

+15.4%

to 20d High

ROE

-66.7%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 1.2

Zentalis Pharmaceuticals: quick answers

What stage is Zentalis Pharmaceuticals in?

As of Oct 22, 2026, Zentalis Pharmaceuticals (ZNTL) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 14, 2026 and is in week 2. What the four stages mean

Is Zentalis Pharmaceuticals in an uptrend?

No. Zentalis Pharmaceuticals is in a Stage 4 downtrend. It trades 30.9% below its 200-day average, which is rising.

How far is Zentalis Pharmaceuticals from its 52-week high?

Zentalis Pharmaceuticals closed at $2.41 on Oct 22, 2026, 63.5% below its 52-week high of $6.61. Its 52-week low is $1.28.

How has Zentalis Pharmaceuticals performed over the past year?

As of Oct 22, 2026, Zentalis Pharmaceuticals is up 47.0% over the past year and up 75.9% so far in 2026.

Which sector and industry is Zentalis Pharmaceuticals in?

Zentalis Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.